Key result
Inhaled nitric oxide from a novel electrochemical generator reduces mPAP in a porcine PAH model.
Why the study?
Clinical cylinder-based inhaled NO delivery is limited by high costs, complex delivery, and supply-chain requirements, creating an unmet need for rapid, affordable, and safe in-home NO generation for PAH.
Does inhaled nitric oxide produced by a novel electrochemical generator improve pulmonary hemodynamics in a porcine model of pulmonary artery hypertension?
Does inhaled nitric oxide produced by a novel electrochemical generator improve pulmonary hemodynamics in a porcine model of pulmonary artery hypertension?
A novel portable electrochemical nitric oxide generator safely and effectively reduced pulmonary arterial pressure and vascular resistance in a porcine model of pulmonary artery hypertension.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for portable electrochemical NO generators in PAH models; human trials needed before clinical translation.
Background Inhaled NO is a selective pulmonary vasodilator proven to be therapeutic for patients with pulmonary artery hypertension (PAH). The most common NO delivery system in clinical practice is cylinder-based, but unfortunately limited by its high costs, complicated delivery, and the requirement of an extensive supply chain, leaving vast unmet medical needs globally. Methods To address the need for rapid, affordable, and safe production of nitric oxide (NO) for in-home inhalation therapy in patients with PAH. We developed a novel portable device to derive NO from a nitrite complex solution with a copper(II)-ligand catalyst, and further examined its effectiveness in a porcine model of PAH. This model was established by using female Bama miniature pig and induced by monocrotaline (MCT) administration. Results This generator could rapidly and safely produce therapeutic NO at concentrations ranging from 0 to 100 parts per million (ppm) with the least disproportionated nitrogen dioxide (NO 2 ) and byproducts. It could effectively alleviate pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in piglets with PAH, without causing major physiologic disruptions. Conclusions Our electrochemical NO generator is able to produce the desired NO doses for pulmonary vasodilation in a safe and sustainable way, with low costs, which paves the way for its subsequent clinical trials in the patient with PAH and other common cardiopulmonary conditions with a high disease burden around the world.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) studied Pulmonary artery hypertension (n=18). Electrochemical NO Generator (ENG) vs. PAH without NO inhalation was evaluated on Mean pulmonary arterial pressure (mPAP) at 2 hours (p=0.006). Inhalation of nitric oxide produced by a novel electrochemical generator significantly reduced mean pulmonary arterial pressure (P=0.006 at 2h) in a porcine model of pulmonary artery hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: